--- title: "Exencial Wealth Advisors LLC Grows Holdings in Danaher Corporation $DHR" description: "Exencial Wealth Advisors LLC increased its stake in Danaher Corporation (NYSE:DHR) by 56.1% in Q2, now owning 18,595 shares valued at $3.67 million. Other institutional investors also raised their sta" type: "news" locale: "en" url: "https://longbridge.com/en/news/262403839.md" published_at: "2025-10-23T10:30:12.000Z" --- # Exencial Wealth Advisors LLC Grows Holdings in Danaher Corporation $DHR > Exencial Wealth Advisors LLC increased its stake in Danaher Corporation (NYSE:DHR) by 56.1% in Q2, now owning 18,595 shares valued at $3.67 million. Other institutional investors also raised their stakes. Danaher stock has a consensus rating of "Moderate Buy" with a target price of $243.39. The company reported Q3 earnings of $1.89 per share, exceeding estimates, and revenue of $6.05 billion, up 4.4% year-over-year. A quarterly dividend was declared, payable on October 31. Exencial Wealth Advisors LLC increased its position in Danaher Corporation (NYSE:DHR - Free Report) by 56.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,595 shares of the conglomerate's stock after acquiring an additional 6,681 shares during the quarter. Exencial Wealth Advisors LLC's holdings in Danaher were worth $3,673,000 at the end of the most recent quarter. - An AI Play Hiding in Plain Sight: A Look at Johnson Controls Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GHP Investment Advisors Inc. boosted its stake in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the period. Sierra Ocean LLC boosted its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares during the period. Red Tortoise LLC boosted its stake in Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate's stock worth $30,000 after purchasing an additional 98 shares during the period. Smallwood Wealth Investment Management LLC bought a new position in Danaher in the 1st quarter worth approximately $31,000. Finally, Ramirez Asset Management Inc. bought a new position in Danaher in the 2nd quarter worth approximately $40,000. 79.05% of the stock is owned by hedge funds and other institutional investors. ## Insiders Place Their Bets In related news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 11.10% of the company's stock. ## Wall Street Analysts Forecast Growth - 3 Stocks Offering Strong Value and Stability Several research analysts have weighed in on the company. Rothschild & Co Redburn restated a "neutral" rating and issued a $220.00 price target (down from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft upped their price target on Danaher from $235.00 to $250.00 and gave the stock a "buy" rating in a research note on Wednesday. Cowen reiterated a "buy" rating on shares of Danaher in a research report on Wednesday. TD Cowen increased their target price on Danaher from $250.00 to $260.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $243.39. **Read Our Latest Research Report on Danaher** ## Danaher Stock Performance - Agilent Technologies Thrives From the Forever Chemicals Crackdown NYSE:DHR opened at $218.06 on Thursday. The stock's fifty day moving average is $202.24 and its 200 day moving average is $197.73. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $260.88. The firm has a market capitalization of $156.14 billion, a PE ratio of 44.96, a PEG ratio of 3.20 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.93% and a net margin of 14.44%.The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the firm posted $1.71 EPS. Danaher's quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year. ## Danaher Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is presently 27.23%. ## About Danaher (Free Report) Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. ## Featured Articles - Five stocks we like better than Danaher - Best ESG Stocks: 11 Best Stocks for ESG Investing - Archer’s Recent String of Victories Signals a New Phase of Growth - Retail Stocks Investing, Explained - 3 Key Stocks Boosting Buybacks Amid Improving Fundamentals - Stock Ratings and Recommendations: Understanding Analyst Ratings - The Best AI for Picking Stocks, Ranked by Performance *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Danaher Right Now? Before you consider Danaher, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list. While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [DHR.US - Danaher](https://longbridge.com/en/quote/DHR.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | BREAKINGVIEWS-丹納赫 100 億美元的併購策略轉變需要信心 | 丹納赫宣佈以 99 億美元收購患者監測系統公司麥斯莫醫療，每股支付 180 美元，較最後收盤價溢價 38%。這一從傳統生物產品的轉型發生在後疫情時期的低迷中，導致投資者反應不一。花旗集團和高盛為丹納赫提供建議，而 Centerview Pa | [Link](https://longbridge.com/en/news/276155581.md) | | 麥斯莫醫療和丹納赫的股票因收購傳聞而出現波動 | 丹納赫公司據報道正在尋求以約 100 億美元收購麥斯莫醫療，導致麥斯莫的股價上漲 34.3%，達到 174.78 美元。這標誌着麥斯莫單日內的顯著漲幅，達到自 6 月以來的最高水平，儘管其年同比虧損為 3.7%。相反，丹納赫的股價下跌 4% | [Link](https://longbridge.com/en/news/276143275.md) | | 第一國家信託公司出售了丹納赫公司（Danaher Corporation）$DHR 的股票 | 第一國家信託公司在第三季度減少了對丹納赫公司（NYSE:DHR）51.6% 的持股，目前持有 7,612 股，價值 151 萬美元。包括先鋒集團和 Geode Capital 在內的其他機構投資者也調整了他們的持股。丹納赫的股票開盤價為 2 | [Link](https://longbridge.com/en/news/275583768.md) | | 併購新聞：丹納赫公司即將達成與麥斯莫醫療價值 100 億美元的交易 | 丹納赫（DHR）即將以 99 億美元收購麥斯莫醫療（Masimo，MASI），這一價格相較於麥斯莫醫療 69.9 億美元的市值具有顯著溢價。該交易可能很快會宣佈，前提是沒有最後時刻的問題。過去一年，MASI 的股價下跌超過 28%，而 DH | [Link](https://longbridge.com/en/news/276103321.md) | | 午間頭條：華納兄弟將尋求派拉蒙的 “最佳和最終” 報價；丹納赫將以 99 億美元收購麥斯莫醫療 | 華納兄弟探索公司正在尋求來自派拉蒙斯凱丹克的 “最終報價”，截止日期為 2 月 23 日，此前 Netflix 已給予豁免。丹納赫已同意以 99 億美元收購麥斯莫醫療。另據消息，雙子座空間站的首席運營官和首席財務官將離職，而 IHS Tow | [Link](https://longbridge.com/en/news/276151237.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.